Clinical Trial Update: Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS [Phase 2, Phase 3]

View source ↗

Summary

A study comparing Haplo-HSCT with Rivogenlecleucel versus Haplo-HSCT with post-transplant cyclophosphamide in AML or MDS was terminated with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Haplo-HSCT
• Rivogenlecleucel ( Rivogenlecleucel)

Snippet

Sponsor: Bellicum Pharmaceuticals | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2023-09-01